1/3/2019, 1:21 PM (Source: TeleTrader)
more TeleTrader news

Merck cancer treatment gets five approvals in Japan

Merck & Co. Inc's Keytruda received five news approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA), the company announced on Thursday. The approvals include that in advanced non-small cell lung cancer to treat melanoma and in advanced microsatellite instability-high (MSI-H) tumors.

"These five simultaneous approvals of KEYTRUDA in Japan represent a significant achievement that involved extensive collaboration with the Japan Pharmaceuticals and Medical Devices Agency... We appreciate the Agency’s efforts to expedite availability of this important medicine to more patients living with cancer in Japan," Merck Research Laboratories chief Dr. Roy Baynes stated.

Keytruda received its first approval from Japan two years ago. The medicine works by enhancing the immune system's ability to identify and fight tumor cells.

Merck shares were down 2.28% premarket on the New York Stock Exchange.

Breaking the News / SS